Published in Blood on September 08, 2005
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med (2015) 2.53
Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol (2011) 2.52
Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood (2009) 2.42
Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood (2013) 2.38
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica (2009) 1.87
The hematopoietic stem cell niche--home for friend and foe? Cytometry B Clin Cytom (2012) 1.70
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). Blood (2007) 1.52
Right on target: eradicating leukemic stem cells. Trends Mol Med (2007) 1.49
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. Oncotarget (2012) 1.34
A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res (2009) 1.30
Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res (2011) 1.29
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy. Leukemia (2008) 1.27
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol (2009) 1.25
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs (2012) 1.22
Aberrant cytokine signaling in leukemia. Oncogene (2007) 1.20
Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood (2007) 1.16
Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood (2010) 1.15
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2011) 1.14
Outlook on PI3K/AKT/mTOR inhibition in acute leukemia. Mol Cell Ther (2015) 1.05
Overexpression of Rheb2 enhances mouse hematopoietic progenitor cell growth while impairing stem cell repopulation. Blood (2009) 1.04
Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells. Adv Enzyme Regul (2009) 1.03
Exploiting cellular pathways to develop new treatment strategies for AML. Cancer Treat Rev (2010) 1.03
Ex vivo rapamycin treatment of human cord blood CD34+ cells enhances their engraftment of NSG mice. Blood Cells Mol Dis (2011) 0.99
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant (2010) 0.95
Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting. Clin Cancer Res (2014) 0.92
mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression. Leukemia (2013) 0.90
SYK regulates mTOR signaling in AML. Leukemia (2013) 0.90
Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol (2007) 0.89
Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med (2012) 0.87
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell Rep (2015) 0.86
SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt. J Hematol Oncol (2013) 0.86
Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res (2007) 0.81
Role for putative hepatocellular carcinoma stem cell subpopulations in biological response to incomplete thermal ablation: in vitro and in vivo pilot study. Cardiovasc Intervent Radiol (2014) 0.81
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.80
The mTOR inhibitor, everolimus (RAD001), overcomes resistance to imatinib in quiescent Ph-positive acute lymphoblastic leukemia cells. Blood Cancer J (2011) 0.80
The emerging role of the phosphatidylinositol 3-kinase/ akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers (Basel) (2010) 0.79
Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. Physiol Genomics (2014) 0.79
The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers (Basel) (2012) 0.78
Harnessing the apoptotic programs in cancer stem-like cells. EMBO Rep (2015) 0.77
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. Int J Hematol Oncol (2013) 0.77
Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation. Haematologica (2015) 0.77
New agents for AML and MDS. Best Pract Res Clin Haematol (2009) 0.76
Rational Combinations of Targeted Agents in AML. J Clin Med (2015) 0.76
What are the endpoints of therapy for acute leukemias? Old definitions and new challenges. Clin Lymphoma Myeloma (2009) 0.76
Phospho-specific flow: fixating on the target. Clin Cancer Res (2012) 0.75
Rapamycin-resistant and torin-sensitive mTOR signaling promotes the survival and proliferation of leukemic cells. BMB Rep (2016) 0.75
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
The phosphoinositide 3-kinase pathway. Science (2002) 24.72
Upstream and downstream of mTOR. Genes Dev (2004) 21.61
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature (2004) 8.76
Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene (2004) 7.92
Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem (1995) 5.57
Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 5.06
Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene (2001) 4.70
Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) (1975) 4.37
Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J Biol Chem (1995) 4.36
Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood (2004) 3.84
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. Proc Natl Acad Sci U S A (1990) 3.70
The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell (2005) 3.59
Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest (1993) 3.57
Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet (2002) 3.31
Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur J Biochem (1991) 3.17
Preferential induction of apoptosis for primary human leukemic stem cells. Proc Natl Acad Sci U S A (2002) 3.12
A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A (2001) 3.01
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood (2003) 2.93
AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A (2001) 2.84
mTOR, translational control and human disease. Semin Cell Dev Biol (2004) 2.77
Antileukemic activity of rapamycin in acute myeloid leukemia. Blood (2004) 2.03
C-kit mutations in core binding factor leukemias. Blood (2000) 1.93
Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol (1977) 1.80
A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood (2001) 1.73
Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia (2003) 1.67
Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood (1999) 1.52
Putting the rap on Akt. J Clin Oncol (2004) 1.51
Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot (Tokyo) (1984) 1.44
Adult acute myeloid leukaemia. Crit Rev Oncol Hematol (2004) 1.37
Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood (2004) 1.26
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias. Leukemia (2004) 1.24
Expression of normal and mutant ras proteins in human acute leukemia. Oncogene (1987) 1.24
Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation (1999) 1.16
Phosphatase and tensin homologue phosphorylation in the C-terminal regulatory domain is frequently observed in acute myeloid leukaemia and associated with poor clinical outcome. Br J Haematol (2003) 1.15
p-Glycoprotein-mediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther (1997) 1.04
Constitutive activation of PI3K is involved in the spontaneous proliferation of primary acute myeloid leukemia cells: direct evidence of PI3K activation. Leukemia (2004) 0.96
The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma (2002) 0.92
Vascular endothelial growth factor receptor-1 and receptor-2 initiate a phosphatidylinositide 3-kinase-dependent clonogenic response in acute myeloid leukemia cells. Exp Hematol (2004) 0.91
Role of umbilical vein endothelial cells in hematopoiesis. Leuk Lymphoma (1998) 0.81
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest (2010) 2.96
Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood (2003) 2.93
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol (2007) 2.90
Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol (2004) 2.54
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell (2009) 2.39
Discovery of agents that eradicate leukemia stem cells using an in silico screen of public gene expression data. Blood (2008) 2.26
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood (2008) 1.88
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci U S A (2011) 1.81
Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia. Cancer Cell (2006) 1.76
A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma (2006) 1.67
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood (2014) 1.64
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
A phase I study of bexarotene, a retinoic X receptor agonist, in non-M3 acute myeloid leukemia. Clin Cancer Res (2008) 1.48
A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clin Cancer Res (2009) 1.42
A new model for the domain structure of heparan sulfate based on the novel specificity of K5 lyase. J Biol Chem (2004) 1.42
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood (2013) 1.41
Elevation in serum lactate at the time of febrile neutropenia (FN) in hemodynamically-stable patients with hematologic malignancies (HM) is associated with the development of septic shock within 48 hours. Cancer Biol Ther (2010) 1.40
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives. Cancer (2010) 1.39
Erythroid dysplasia, megaloblastic anemia, and impaired lymphopoiesis arising from mitochondrial dysfunction. Blood (2009) 1.37
Validating a custom multiplex ELISA against individual commercial immunoassays using clinical samples. Biotechniques (2007) 1.28
A common genetic mechanism in malignant bone marrow diseases. N Engl J Med (2009) 1.23
Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia. Arch Intern Med (2004) 1.23
BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell (2004) 1.22
Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res (2007) 1.16
Single-cell pharmacodynamic monitoring of S6 ribosomal protein phosphorylation in AML blasts during a clinical trial combining the mTOR inhibitor sirolimus and intensive chemotherapy. Clin Cancer Res (2011) 1.14
Myelodysplastic syndromes: clinical practice guidelines in oncology. J Natl Compr Canc Netw (2013) 1.12
Crenolanib is a selective type I pan-FLT3 inhibitor. Proc Natl Acad Sci U S A (2014) 1.12
Mutations in the Arabidopsis phosphoinositide phosphatase gene SAC9 lead to overaccumulation of PtdIns(4,5)P2 and constitutive expression of the stress-response pathway. Plant Physiol (2005) 1.11
Multiplex RT-PCR for the detection of leukemia-associated translocations: validation and application to routine molecular diagnostic practice. J Mol Diagn (2003) 1.10
BCR-ABL kinase is dead; long live the CML stem cell. J Clin Invest (2010) 1.00
Medical students, medical schools and international health. Med J Aust (2007) 0.98
Dynamic evolution of clonal epialleles revealed by methclone. Genome Biol (2014) 0.97
Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion (2010) 0.96
p38 MAP kinase inhibitors. Part 5: discovery of an orally bio-available and highly efficacious compound based on the 7-amino-naphthyridone scaffold. Bioorg Med Chem Lett (2006) 0.94
Short hairpin RNA screen reveals bromodomain proteins as novel targets in acute myeloid leukemia. Cancer Cell (2011) 0.94
Interferon regulatory factor-8-driven myeloid differentiation is regulated by 12/15-lipoxygenase-mediated redox signaling. Exp Hematol (2010) 0.93
p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors. Blood (2007) 0.93
TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. Blood (2002) 0.93
Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia. Cancer (2013) 0.92
Myelodysplastic syndromes and autoimmune diseases--case series and review of literature. Leuk Res (2013) 0.92
Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem (2010) 0.90
Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol (2011) 0.90
BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. J Biol Chem (2008) 0.90
Enhanced growth of myelodysplastic colonies in hypoxic conditions. Exp Hematol (2007) 0.89
Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol (2007) 0.87
Novel 1-(2-aminopyrazin-3-yl)methyl-2-thioureas as potent inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem Lett (2009) 0.86
Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis. Leuk Res (2012) 0.86
An evolutionary explanation for the presence of cancer nonstem cells in neoplasms. Evol Appl (2012) 0.82
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leuk Lymphoma (2013) 0.81
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome. Invest New Drugs (2013) 0.81
Targeted signal transduction therapies in myeloid malignancies. Curr Oncol Rep (2010) 0.80
Mechanism of Janus kinase 3-catalyzed phosphorylation of a Janus kinase 1 activation loop peptide. Arch Biochem Biophys (2003) 0.79
p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design. Bioorg Med Chem Lett (2006) 0.79
Evidence of myeloid differentiation in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene. Cancer Biol Ther (2007) 0.79
Intrinsic resistance to JAK2 inhibition in myelofibrosis. Clin Cancer Res (2013) 0.79
Time-resolved Forster resonance energy transfer assays for the binding of nucleotide and protein substrates to p38alpha protein kinase. Anal Biochem (2005) 0.79
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation. Br J Haematol (2013) 0.77
Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones. J Med Chem (2003) 0.77
Myeloid blastic transformation of myeloproliferative neoplasms--a review of 112 cases. Leuk Res (2010) 0.76
BCR/ABL and chromosomal instability: debate resolved. Blood (2012) 0.76
Increased cerebral blood flow after leukapheresis for acute myelogenous leukemia. Am J Hematol (2007) 0.76
Phase II trial of clofarabine and daunorubicin as induction therapy for acute myeloid leukemia patients greater than or equal to 60 years of age. Leuk Res (2013) 0.76
p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones. Bioorg Med Chem Lett (2003) 0.75
Synthesis and biological activity of 2H-quinolizin-2-one based p38alpha MAP kinase inhibitors. Bioorg Med Chem Lett (2010) 0.75
Lack of healthcare information--a hidden killer. Midwives (2014) 0.75
Use of plasma exchange, steroids, and anticoagulation in a patient with multiple arterial thromboses and IgM anticardiolipin antibodies. J Clin Apher (2002) 0.75
p38 MAP kinase inhibitors. Part 3: SAR on 3,4-dihydropyrimido[4,5-d]pyrimidin-2-ones and 3,4-dihydropyrido[4,3-d]pyrimidin-2-ones. Bioorg Med Chem Lett (2006) 0.75
p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett (2005) 0.75
Synthesis and biological activity of pyridopyridazin-6-one p38 MAP kinase inhibitors. Part 1. Bioorg Med Chem Lett (2010) 0.75
Synthesis and biological activity of pyridopyridazin-6-one p38α MAP kinase inhibitors. Part 2. Bioorg Med Chem Lett (2012) 0.75